Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal

J Małyszko1, J S Małyszko, T Hryszko

  • 1Department of Nephrology and Internal Medicine, Medical School, PL-15-540 Białystok, Zurawia 14, Poland. jolmal@poczta.snet.pl

Insights

Simvastatin effectively lowers lipids and improves platelet function and endothelial health in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). This statin therapy offers benefits for cardiovascular risk factors in this high-risk population.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Uremia frequently causes lipid, hemostasis, and platelet function disturbances, increasing atherosclerosis and thrombotic risks.
  • Continuous ambulatory peritoneal dialysis (CAPD) patients have high risks of dyslipidemia and cardiovascular death.
  • Statins show promise in improving lipid profiles and hemostasis in uremic patients.

Purpose of the Study:

  • To evaluate the effects of simvastatin on platelet functions, hemostatic parameters, and serum lipids in hyperlipidemic CAPD patients.
  • To assess changes over a 6-month treatment period.

Main Methods:

  • Eight hyperlipidemic CAPD patients received 10 mg of simvastatin daily.
  • Platelet aggregation was measured in whole blood and platelet-rich plasma (PRP) using collagen, arachidonic acid, ADP, and ristocetin.
  • Serum lipids, P-selectin, fibrinolytic activity index, thrombomodulin, and prothrombin fragments 1+2 were also assessed at baseline and after 1, 3, and 6 months.

Main Results:

  • Simvastatin significantly reduced whole-blood and PRP platelet aggregation induced by collagen and ADP, and ristocetin-induced aggregation in PRP.
  • Significant improvements were observed in fibrinolytic activity and reduced thrombomodulin levels, indicating better endothelial function.
  • Cholesterol and LDL levels decreased significantly within 1 month and remained low throughout the study.

Conclusions:

  • Simvastatin is an effective hypolipidemic agent in CAPD patients.
  • The therapy favorably impacts platelet aggregation, endothelial function, and fibrinolysis.
  • Simvastatin may help mitigate cardiovascular risks in this patient population.
Abstract

Related Concept Videos

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...